Early childhood developmental health and autism diagnosis
Cognoa (cognoa.com) earns a Brand Analyzer score of 71 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Cognoa ranks in the 68th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 97/100, Digital Presence 76/100, Visual Identity 96/100, Messaging Clarity 95/100, Trust Foundation 67/100, AI Discoverability 85/100, Brand Authority 23/100.
Cognoa is a digital health company focused on early childhood developmental health and autism diagnosis. Its flagship product, Canvas Dx, is the first FDA-authorized diagnostic solution for autism in children ages 1.5 to 6. The platform delivers diagnosis within days rather than months or years and is reimbursed by insurance. Cognoa's stated mission is to make early diagnosis and interventions accessible, with particular attention to underserved populations.
| Brand Name | Cognoa |
|---|---|
| Domain | cognoa.com |
| Industry | Healthcare |
| Main Competitors | Autism Speaks, Tele-Behavioral Health (Teladoc), Behavioral Innovations, Cortica, Springtide Child Development |
Moz Domain Authority 40/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Cognoa: early childhood developmental health and autism diagnosis" (Meta description: 8 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on Facebook, X (Twitter), YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Cognoa scores 35/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Cognoa has a weak AI-visibility profile at 35/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (63/100) and its weakest is visibility (13/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 40/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Cognoa's main competitors include Autism Speaks, Tele-Behavioral Health (Teladoc), Behavioral Innovations, Cortica, Springtide Child Development. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Cognoa official site
Cognoa's primary product is Canvas Dx, the first FDA-authorized diagnostic solution for autism in children ages 1.5 to 6. Canvas Dx is designed to deliver rapid diagnosis within days and is now reimbursed by insurance. The company's broader focus is on early childhood developmental health and interventions, though specific additional products or services beyond Canvas Dx are not detailed in the available facts.
Sources: Cognoa official site
Popular alternatives to Cognoa include Autism Speaks, Tele-Behavioral Health (Teladoc), Behavioral Innovations, Cortica, Springtide Child Development. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Cognoa official site
Cognoa is a digital health company specializing in early childhood developmental health and autism diagnosis. It developed Canvas Dx, described as the first FDA-authorized diagnostic solution for autism in children ages 1.5 to 6. The company operates at the intersection of clinical technology and pediatric healthcare, aiming to make early diagnosis and interventions available to children and families, including those in underserved communities.
Sources: Cognoa official site
Cognoa has limited AI-search visibility, scoring 35/100 on Brand Analyzer's AI visibility composite (visibility 13, trust 45, recommendation 63). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Cognoa official site
Cognoa develops and provides digital diagnostic tools for early childhood developmental health, with a focus on autism. Its primary product, Canvas Dx, enables clinicians to diagnose autism in children ages 1.5 to 6 within days, compared to the traditional process that can take months or years. Cognoa also aims to expand equitable access to diagnosis, particularly for underserved populations, and its solution is reimbursed by insurance.
Sources: Cognoa official site
Cognoa and Autism Speaks are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Cognoa official site
Cognoa is known for Canvas Dx, the first FDA-authorized diagnostic solution for autism spectrum disorder in children ages 1.5 to 6. The product is notable for dramatically reducing the time to diagnosis - delivering results within days rather than the months or years typically associated with traditional diagnostic pathways. Cognoa is also recognized for its focus on equitable access to autism diagnosis for underserved pediatric populations.
Sources: Cognoa official site
Cognoa scores 63/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Cognoa official site
Cognoa's products and services are used by clinicians, parents, and families of children ages 1.5 to 6 who have developmental concerns, particularly those seeking autism diagnosis. The company places particular emphasis on serving underserved populations who may face barriers to timely diagnosis through traditional healthcare pathways. Insurance reimbursement broadens the potential user base across different socioeconomic groups.
Sources: Cognoa official site
Cognoa's Canvas Dx has received FDA authorization, which indicates it has undergone regulatory review for safety and efficacy as a diagnostic solution. The product has also been associated with clinical trials, as reflected in available knowledge-graph descriptions. Additionally, Canvas Dx is now reimbursed by insurance, suggesting acceptance within established healthcare and payer systems. These factors point to a degree of institutional validation, though independent assessments are not detailed in the available facts.
Sources: Cognoa official site
Cognoa can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Cognoa official site
Cognoa has gained attention primarily because Canvas Dx addresses a significant gap in pediatric healthcare: the long wait times associated with autism diagnosis. By reducing diagnosis time from months or years to days and making the solution accessible to underserved populations, Cognoa addresses both speed and equity concerns. Insurance reimbursement further increases its accessibility and adoption among clinicians and families seeking timely answers for children with developmental concerns.
Sources: Cognoa official site
Ranked closest to Cognoa: Codoxo (71/100), ClinIntell (71/100), Premier (71/100), Continuum Systems (71/100).
A step up - brands to learn from: Zipline (81/100), Zimmer Biomet (81/100).
Category leader: Dassault Systèmes (95/100).